Tirzepatide, a dual GIPR/GLP-1R agonist approved for T2D and obesity, has shown preclinical neurobiological effects consistent with neuroprotection in models of diabetic neurodegeneration, Alzheimer-type amyloidosis, and Parkinsons disease
Much of the benefit appears to come from the central nervous system, Habegger said
Types of GLP-1 medications GLP-1 therapies are available in several different forms: Once-weekly injections Daily oral or injectable options Combination therapy with insulins Xultophy (insulin degludec + liraglutide) IcoSema (weekly insulin Icodec + Semaglutide) Soliqua (insulin glargine and lixisenatide) How the main GLP-1 drugs compare While all GLP-1 medications work through similar mechanisms, they differ in strength, dosing frequency, weight loss effects, and side-effect profiles
All recommendations by the ADA regarding GLP-1 RAs have been assigned an A rating, which is the associations highest rating of evidence
Varga M, Jjrt R, Fnad P, Mihly R, Palgyi A
GLP-1 agonists were on the market in 2005 with exenatide